| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BDH2 |
| Uniprot No | Q9BUT1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-245aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGRLDGKVIILTAAAQGIGQAAALAFAREG AKVIATDINESKLQELEKYPGIQTRVLDVTKKKQIDQFANEVERLDVLFN VAGFVHHGTVLDCEEKDWDFSMNLNVRSMYLMIKAFLPKMLAQKSGNIIN MSSVASSVKGVVNRCVYSTTKAAVIGLTKSVAADFIQQGIRCNCVCPGTV DTPSLQERIQARGNPEEARNDFLKRQKTGRFATAEEIAMLCVYLASDESA YVTGNPVIIDGGWSL |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BDH2重组蛋白的示例参考文献(注：文献为模拟示例，实际引用请核实真实来源)：
---
1. **"Recombinant Expression and Functional Analysis of Human BDH2 in Iron Metabolism"**
*作者：Li, X. et al.*
摘要：本研究通过在大肠杆菌中成功表达并纯化人源BDH2重组蛋白，证实其催化合成2.5-二羟基苯甲酸(2.5-DHBA)的能力，并揭示其在调节细胞铁稳态中的关键作用。
2. **"Structural Characterization of BDH2: A Key Enzyme in Siderophore Biosynthesis"**
*作者：Zhang, Y. et al.*
摘要：利用X射线晶体学解析BDH2重组蛋白的三维结构，阐明其底物结合位点及催化机制，为靶向铁代谢疾病的药物设计提供结构基础。
3. **"BDH2 Recombinant Protein Enhances Cellular Resistance to Ferroptosis"**
*作者：Wang, H. et al.*
摘要：通过体外实验证明，纯化的BDH2重组蛋白能够通过调控脂质过氧化过程抑制铁死亡，为神经退行性疾病治疗提供新思路。
4. **"Optimization of BDH2 Expression in Pichia pastoris for High-Yield Production"**
*作者：Chen, J. et al.*
摘要：系统优化毕赤酵母表达系统中BDH2重组蛋白的分泌表达条件，显著提高蛋白产量及活性，推动其在工业酶学中的应用。
---
建议通过PubMed或Google Scholar搜索关键词“BDH2 recombinant protein”“BDH2 iron metabolism”获取最新文献。
**Background of BDH2 Recombinant Protein**
BDH2 (3-Hydroxybutyrate Dehydrogenase 2) is a mitochondrial enzyme belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. It catalyzes the reversible conversion of α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D-2HG) using NADH as a cofactor, linking it to cellular metabolism and redox regulation. Unlike its isoform BDH1. which primarily participates in ketone body metabolism, BDH2 has broader roles, including iron homeostasis through its interaction with the iron chaperone PCBP1 and modulation of labile iron pools.
BDH2 gained attention due to its association with pathological conditions. Elevated D-2HG levels, driven by BDH2 activity, are implicated in metabolic disorders and cancers, as D-2HG inhibits α-KG-dependent dioxygenases, altering epigenetic regulation and hypoxia signaling. Additionally, BDH2 dysfunction is linked to neurodegenerative diseases, as disrupted iron metabolism contributes to oxidative stress and neuronal damage.
Recombinant BDH2 protein is engineered for *in vitro* studies to dissect its enzymatic mechanisms, substrate specificity, and interactions with metabolic pathways. It is typically produced in bacterial or mammalian expression systems, purified via affinity tags, and validated for activity. Researchers utilize this tool to explore therapeutic strategies targeting metabolic syndrome, cancer, or neurodegeneration. For instance, inhibiting BDH2 could reduce oncogenic D-2HG in certain malignancies, while enhancing its activity might alleviate iron-related disorders. Its study also sheds light on mitochondrial dysfunction and cellular adaptation to metabolic stress, making BDH2 a versatile target in both basic research and drug development.
×
